Table 1.
Characteristics of patients with hematological malignancies KPC-K.pneumoniae carriers who developed KPC-K.pneumoniae BSI
| Period 1: March 2012–Dec 2013 N 18 |
Period 2: Jan 2017–Oct 2018 N 16 |
p-value (absolute difference; 95% CI) | |
|---|---|---|---|
| Male | 7 (39%) | 6 (37%) | 0.2 (0.02; -0.31 to 0.34) |
| Mean age, years (range) | 47.3 (28–68) | 50.8 (3–68) | 0.07 (-3.5; -13.2 to 6.24)a |
| Acute leukemia | 16 (89%) | 12 (75%) | 0.2 (0.14; -0.11 to 0.39) |
| - Myeloid | 12/16 (75%) | 10/12 (83%) | 0.4 (0.08; -0.38 to 0.21) |
| Other hematological diseases | 2 (11%) | 4 (25%) | 0.2 (0.14; -0.39 to 0.11) |
| Intensive chemotherapy | 15 (83%) | 12 (75%) | 0.4 (0.08; -0.19 to 0.35) |
| Allogeneic HSCT | 1 (6%) | 4 (25%) | 0.1 ( -0.19; -0.43 to 0.04) |
| Other treatment | 2 (11%) | 0 (0%) | 0.2 (0.11; -0.03 to 0.25) |
| Length of neutropenia episode (mean days, range) | |||
| - With < 1000 neutrophils/cmm | 17.6 (5–35) | 21.1 (11–40) | 0.3 (-3.50; -9.2 to 2.2)a |
| - With < 100 neutrophils/cmm | 8.4 (0–17) | 12.5 (6–25) | 0.07 (-4.1; -7.86 to -0.31)a |
| N. of KPC-K.pneumonia carriers identified during the period | 27 | 88 | |
| Carriers who developed K.pneumonia BSI | 18 (67%) | 16 (11%) | < 0.01 (0.48; 0.29 to 0.68) |
aContinuous variables were compared using Kruskal–Wallis test